KSKantrol Kumar Sahu

Kantrol Kumar Sahu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kantrol Kumar Sahu has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Nanoparticle-Based Drug Delivery Systems: Evaluating Toxicological Impacts and Safety Measures

    by Kantrol Kumar Sahu, Sandeep Singh, Suman Sinha, Rishabh Pratap Singh, Virendra Kumar Kushwaha

    Nanotechnology has advanced rapidly in recent years, playing a significant role in fields such as pharmaceuticals and cosmetics. Its applications, including drug delivery systems and sunscreens, have demonstrated considerable benefits. In particular, nanomaterials enhance product stability and efficacy by enabling improved pharmacological responses and better protection against UV radiation. Despite these advances, concerns are growing regarding the potential toxicological effects of nanomaterials on human health and the environment. Studies indicate that certain sunscreen chemicals, once washed off human skin, can enter aquatic ecosystems via wastewater systems, potentially harming marine life. Nanomaterials, typically defined as having at least one dimension smaller than 100 nanometers, possess unique physicochemical properties that influence their behavior in biological systems. As their use increases, so does the risk of unintended environmental release, making it essential to assess their biocompatibility, distribution, and long-term impacts before widespread application. Although some research has explored the toxicity of nanomaterials, the mechanisms underlying their harmful effects remain incompletely understood. Factors such as particle size, shape, surface characteristics, dissolution rate, density, and structural defects are major contributors to cytotoxicity and environmental risk. A deeper understanding of how these properties interact with living systems is crucial for the safe and responsible development of nanotechnology-based products.

  • Nanotheranostic Approach for Targeting Tauopathies in Alzheimer's Disease: Mechanistic Insight and Recent Advances

    by Kantrol Kumar Sahu, Ruchi Chaudhary, Mohd. Asad Farooqi, Monika Kaurav

    The most prevalent type of dementia, Alzheimer's disease (AD), is typified by the presence of intracellular tau protein neurofibrillary tangles and extracellular amyloid plaques. There are currently about 50 million people who have dementia, and by 2030, that number is predicted to rise to 75 million, placing a significant financial strain on the nation's healthcare system. Novel disease-modifying treatments are desperately needed to combat this illness, given the consequences on patients' quality of life and the mounting financial strain. There are currently no disease- modifying medications available; instead, the majority of available therapies are symptomatic ones such as cholinesterase inhibitors and N-methyl-D-aspartate receptor blockers. The primary focus of therapeutic research against AD has shifted to tau-targeting strategies following multiple unsuccessful attempts to create medications against amyloidopathy. This article first provides an introduction to tauopathy in AD before summarizing current research on the creation of tau-oriented multi-target directed ligands and small compounds as therapies that target tau alteration, aggregation, and degradation. The overall goal of this work is to present a thorough and critical review of small compounds that are being investigated as potential treatment candidates for AD tauopathy.


  • Open Access

    Amelioration of Cognitive Deficit by Moringa oleifera flower extract in a Scopolamine-Induced Alzheimer’s Disease-Like Condition in a Rat Model

    by Kantrol Kumar Sahu

    The Asian Journal of Pharmaceutics is a peer-reviewed open-access medical journal published by Medknow Publications on behalf of the B.R. Nahata Smriti Sansthan (Memorial Trust) (Mandsaur, India). Articles address topics in pharmaceutics, biopharmaceutics, pharmaceutical chemistry, pharmacognosy, pharmacology, pharmaceutical analysis, pharmacy practice, and clinical and hospital pharmacy.

  • Advances and Challenges of Microneedle Assisted Drug Delivery for Biomedicals Applications: A Review

    by Shiv Bahadur, Radhika, Kantrol Kumar Sahu, Arun Kumar Singh

    Microneedles have been explored as a novel way of delivering active ingredients into the skin. They have various advantages, such as quick and efficient drug delivery, mechanical stability, minimal pain, variable capacity and easy use. Microneedles are enabled for the delivery of vaccine, peptides, medicinal components and in cosmetology, which couldn’t go unnoticed. The novel approaches in the transdermal drug delivery system have increased the efficiency of drug delivery into the skin by crossing the skin barriers. This platform has a wide range of applications and can also be used to deliver non-transdermal biomedicals. The variety in the design of microneedles has demanded similar diversity in their methods of fabrication; micro molding and drawing lithography may be useful methods. There are different types of polymers and materials for the fabrication of microneedles. Several synthetic and natural materials are used in the fabrication of microneedles. Unique shapes, materials, and mechanical properties are modified for organ-specific applications in microneedle engineering. In this review, we discuss several factors and their roles to cross the biological barriers for transdermal drug delivery in various sites, such as in ocular, vascular, oral, and mucosal tissue. Additionally, this article highlights the future scope of transdermal drug delivery systems through microneedles.

  • Unveiling the transformative horizon of biopolymers in drug delivery

    by Pranjal Mishra, Braj Rawat, Kantrol Kumar Sahu, Wasim Akram


  • Role of Phytoactive-based Nanoformulation for the Treatment of Arthritis

    by Shivendra Kumar, Kantrol Kumar Sahu, Mohit Agrawal, Kuldeep Singh, Sunam Saha

    Joints and arthritic conditions are among the most dangerous illnesses that humans have ever encountered and it is even more worrying that there is no recognized treatment for arthritis. The researchers looked for safer alternatives, such as herbal medicines, because the traditional treatments used to treat severe joint inflammatory issues have several negative side effects. A ligand-coated nanomedicine can bind to receptors that are overexpressed by cells in chronically inflammatory tissues, increasing its efficacy and reducing its systemic side effects. This is because the pathophysiology of rheumatoid arthritis suggests that macrophages and overexpressed molecules exist within inflamed tissues, which increases permeability and allows nanomedicines to accumulate in inflamed tissue and cause retention phenomena. The anti-arthritic properties of a variety of plants, their components, extracts, and phyto-isolates have been studied to date. These plant compounds can pose stability and delivery problems, which restricts their efficacy as a treatment for inflammatory diseases. The multifunctional and adaptable features of different nanoparticles can help herbal remedies based on nanotechnology get beyond the delivery constraints of different natural ingredients. The application of nanoformulations in tissue engineering is an additional strategy for delivering drugs directly to bone and cartilage in RA patients. The medication is more therapeutically effective due to nanoformulation's improved synovium and cartilage absorption, accumulation, and penetration at inflammatory joints. Herbal medications with a nanotechnology foundation exhibit superior pharmacokinetic and drug delivery qualities, aid in better oral absorption, regulate drug release, boost in vivo retention capacity, target delivery, and have synergistic effects. This review provides an update on the use of herbal medicines based on nanotechnology, which show promise in treating arthritis and other ailments.


  • A Comprehensive Review on Preclinical Alzheimer's Disease Models: Evaluating their Clinical Relevance

    by Virendra Kushwaha, Kantrol Kumar Sahu

    Alzheimer's disease (AD) is a neurological disorder that increases with age and must be treated immediately by worldwide healthcare systems. Internal neurofibrillary tau tangles and extracellular amyloid accumulation have been widely recognized as the primary causes of Alzheimer's disease. These degenerative age-related ailments are expected to proliferate exponentially as life expectancy rises. Experimental models of AD are essential for acquiring a deep knowledge of its pathogenesis and determining the viability of novel therapy options. Although there isn't a model that encompasses all the characteristics of real AD, these models are nonetheless highly helpful for the research of various modifications associated with it, even though they are only partially indicative of the disease circumstances being studied. Better knowledge of the advantages and disadvantages of each of the different models, as well as the use of more than one model to evaluate potential medications, would increase the effectiveness of therapy translation from preclinical research to patients. We outline the pathogenic characteristics and limitations of the main experimental models of AD in this review, including transgenic mice, transgenic rats, primates and non-primate models along with in-vitro cell culture models in humans. Additionally, it highlights the possible future of experimental modeling of AD and includes the co-morbid models.


  • Effect of Toll-like Receptor-3 Antagonist on Viral Asthma Exacerbations Via a TLR3/dsRNA Complex Pathway

    by Swamita Arora, Mohit Agrawal, Kantrol Kumar Sahu, Sanjar Alam, Wasim Akram, Mohammad Khalid, Shivendra Kumar, Sunam Saha, Kuldeep Singh, Hema Chaudhary

    Background: The Toll-like receptor-3 (TLR3) ligand Poly(I:C) has been shown to induce a viral aggravation of severe asthma by identifying double-stranded RNA (dsRNA). This study aimed to evaluate the therapeutic role of the TLR3/dsRNA complex inhibitor-calbiochem compound in the treatment of Poly(I:C)-induced viral asthma exacerbations through the ovalbu-min-induced asthma model in Swiss albino mice. Methods: Poly(I:C) and Ovalbumin drugs were injected in mice to sensitize (i.p. on 0, 7, and 14th day) and challenge (i.n. on the 21st and 22nd days). In contrast, the treatment drug TLR3/dsRNA complex inhibitor-calbiochem was given on the 21st and 22nd days intraperitoneally within the study period. In-vivo measurements were carried out in BALF and serum for pro-inflammatory cytokines, inflammatory leukocyte counts, lactate dehydrogenase (LDH) and nitrite levels, lungs/body weight index, and lung tissue histopathology using H and E staining in mice airways. Results: High levels of cytokines (NF-κB, IL-1β, IL-5, RANTES, MIP-2, and MCP-1) are seen in groups exposed to OVA and Poly (I:C). Further, inflammatory leukocyte cell counts, lung-body weight (LW/BW) index, airway hyperresponsiveness (AHR), and lung tissue damage sug-gest exacerbations in mice airways. On the other hand, TLR3/dsRNA complex inhibitor-calbio-chem and dexamethasone significantly reversed these changes toward normal levels. Conclusions: These results suggest that the novel compound TLR3/dsRNA complex inhibitor-calbiochem has a better therapeutic role than dexamethasone for managing inflammatory char-acteristics in asthmatic mice lungs and is a potent target for viral asthma exacerbations

  • Nanoparticulate mediated transcutaneous immunization: Myth or reality

    by Monika Kaurav, Sunita Minz, Kantrol Sahu, Manoj Kumar, Jitender Madan, Ravi Shankar Pandey